• Estrogen exposure modulates lipid metabolism and cardiovascular risk, as multiple studies link estrogen therapy or administration with altered serum lipids and atherosclerotic outcomes in both sexes and across disease states [4], [20], [1], [3], [14], [12].

• Menopause biology and ovarian aging are framed around endogenous hormone activity and timing, with work showing ovarian function after menopause, age at menopause, and hormonal activity markers (urinary estrogens, vaginal smears, gonadotropins) to map menopausal transition [5], [16], [19], [8], [10].

• Therapeutic estrogen applications span cardiovascular, dermatologic, and cancer risk contexts, with clinical studies of estrogen therapy in coronary disease or MI, acne therapy, and cancer risk implications of exogenous estrogens/progestins, highlighting benefits and safety concerns [1], [12], [11], [13], [14].

• Endocrine measurement and mechanism-focused work cluster around methods to quantify estrogens and gonadotropins, plus estrogenic modulation of metabolism and tissue properties (ground substance and hydrocortisone binding), illustrating early endocrine biomarker development [8], [10], [18], [6].

• Hormonal loss and CHD risk: evidence that loss of ovarian hormones or estrogen absence correlates with higher CHD incidence, implying protective cardiovascular role of ovarian hormones, supported by castration studies and hormone therapy outcomes [7], [1], [12].